What is Atosiban?
Atosiban is a synthetic nonpeptide desamino-oxytocin analog and a competitive vasopressin or oxytocin receptor antagonist. It is used in after assisted reproduction, preterm birth and to halt premature labour due to its ability to decrease contractions and improve uterine receptivity by reducing intracytoplasmic calcium release and downregulate prostaglandin synthesis.
Global Atosiban Market Outlook
Atosiban is a potent stimulator of myometrial contractions and plays an important role in the initiation of both term and preterm labour. Increasing incidence of preterm birth is driving the growth of the atosiban market. An increase in the incidence of multiple pregnancies, infections and chronic conditions such as diabetes and high blood pressure among pregnant women is the factor to fuel prevalence. According to the World Health Organization, every year, an estimated 15 million babies are born preterm and this figure is rising year by year. Across 184 countries, the rate of preterm birth ranges from 5% to 18% of babies born. The burden of preventing deaths and complications from preterm birth with a healthy pregnancy is high. These deaths incidence is needed to be prevented with current, cost-effective interventions. However, associated regulatory affairs, lack of hospital facilities and inadequate education about prenatal care in rural areas restrains the growth of the market. Also, atosiban is approved only in 67 countries, excluding the USA and Japan.
Global Atosiban Market Competitive Landscape
The "Global Atosiban Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such Ferring Pharmaceuticals, Sun Pharma, Shanghai Soho-Yiming Pharmaceuticals, EVER Pharma, Hangzhou Longshine Bio-Tech, Cayman Chemical and Neore Pharmaceutical. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis.
Customization of the Report
• In case of any queries or customization requirements please connect with our sales team, who will ensure that your requirements are met.
1. INTRODUCTION OF GLOBAL ATOSIBAN MARKET
1.1. Overview of the Market
1.2. Scope of Report
1.3. Assumptions
2. EXECUTIVE SUMMARY
3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1. Data Mining
3.2. Validation
3.3. Primary Interviews
3.4. List of Data Sources
4. GLOBAL ATOSIBAN MARKET OUTLOOK
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Porters Five Force Model
4.4. Value Chain Analysis
5. GLOBAL ATOSIBAN MARKET, BY TYPE
5.1. Overview
5.2. Injection
5.3. Concentrate
6. GLOBAL ATOSIBAN MARKET, BY APPLICATION
6.1. Overview
6.2. Preterm Birth
6.3. Other
7. GLOBAL ATOSIBAN MARKET, BY GEOGRAPHY
7.1. Overview
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.3. Europe
7.3.1. Germany
7.3.2. U.K.
7.3.3. France
7.3.4. Rest of Europe
7.4. Asia Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. Rest of Asia Pacific
7.5. Rest of the World
7.5.1. Latin America
7.5.2. Middle East & Africa
8. GLOBAL ATOSIBAN MARKET COMPETITIVE LANDSCAPE
8.1. Overview
8.2. Company Market Ranking
8.3. Key Development Strategies
9. COMPANY PROFILES
9.1. Ferring Pharmaceuticals
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
9.2. Sun Pharma
9.2.1. Overview
9.2.2. Financial Performance
9.2.3. Product Outlook
9.2.4. Key Developments
9.3. Shanghai Soho-Yiming Pharmaceuticals
9.3.1. Overview
9.3.2. Financial Performance
9.3.3. Product Outlook
9.3.4. Key Developments
9.4. EVER Pharma
9.4.1. Overview
9.4.2. Financial Performance
9.4.3. Product Outlook
9.4.4. Key Developments
9.5. Hangzhou Longshine Bio-Tech
9.5.1. Overview
9.5.2. Financial Performance
9.5.3. Product Outlook
9.5.4. Key Developments
9.6. Cayman Chemical
9.6.1. Overview
9.6.2. Financial Performance
9.6.3. Product Outlook
9.6.4. Key Developments
9.7. Neore Pharmaceutical
9.7.1. Overview
9.7.2. Financial Performance
9.7.3. Product Outlook
9.7.4. Key Developments
10. Appendix
10.1. Related Reports
| Price : US$ 3500 | Date : Aug 2023 |
| Category : Healthcare and Pharmaceuticals | Pages : 166 |
| Price : US$ 3500 | Date : Oct 2022 |
| Category : Healthcare and Pharmaceuticals | Pages : 149 |
| Price : US$ 3500 | Date : May 2022 |
| Category : Healthcare and Pharmaceuticals | Pages : 130 |
| Price : US$ 3500 | Date : Jun 2022 |
| Category : Healthcare and Pharmaceuticals | Pages : 130 |
| Price : US$ 3500 | Date : Jun 2022 |
| Category : Healthcare and Pharmaceuticals | Pages : 130 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
Request Sample 
Request Discount 
Inquire Before Buy
